|
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes
|
Apr 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH).
|
Oct 2013
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Myelodysplastic syndromes: Contemporary review and how we treat
|
Jan 2016
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia
|
Jan 2014
|
Am J Hematol
|
aplastic anemia
|
|
Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
|
Mar 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience
|
Aug 2017
|
Am J Hematol
|
aplastic anemia
|
|
Impact of comorbidities by ACE-27 in the Revised-IPSS for patients with myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
|
Aug 2012
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
